Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19838602 | 0.95 | GPR119 (0.61) | GPR119MEN1KMT2ACHEK2ALDH1A1 | |
| SCHEMBL3377761 | 0.92 | GPR119 (0.57) | GPR119MEN1KMT2ACHEK2ALDH1A1 | |
| SCHEMBL19838626 | 0.92 | GPR119 (0.57) | GPR119MEN1KMT2ACHEK2ALDH1A1 | |
| SCHEMBL5534425 | 0.90 | GPR119 (0.55) | GPR119MEN1KMT2ACHEK2ALDH1A1 | |
| SCHEMBL264162 | 0.88 | GPR119 (0.67) | GPR119CHEK2ALDH1A1KDM1AHRH3 | |
| SCHEMBL74203 | 0.88 | GPR119 (0.67) | GPR119CHEK2ALDH1A1HRH3USP30 | |
| SCHEMBL12533230 | 0.88 | GPR119 (0.67) | GPR119CHEK2ALDH1A1MMP13 | |
| SCHEMBL2735422 | 0.88 | GPR119 (0.67) | GPR119KMT2ACHEK2ALDH1A1HRH3 | |
| SCHEMBL5538341 | 0.87 | GPR119 (0.63) | GPR119CHEK2ALDH1A1USP30MMP13 | |
| SCHEMBL2951108 | 0.87 | GPR119 (0.63) | GPR119CHEK2ALDH1A1HRH3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014173-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-19 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11180472-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2021-11-23 | — | — | US | disclosed |
| US-20200239434-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2020-07-30 | — | — | US | disclosed |
| US-20190330189-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-31 | — | — | US | disclosed |
| US-10364232-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2019-07-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180186768-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-05 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2079693-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052899-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| EP-1534677-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | Pfizer Products Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063759-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004009550-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180472-B2 | Antibacterial compounds | FDPS, SQOR, NDUFS3 | GPR119 4679/4885MEN1 2036/4885KMT2A 4441/4885 |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | GPR119 1545/4885MEN1 4388/4885KMT2A 572/4885 |
| US-20190330189-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, SQOR, NDUFS3 | GPR119 4679/4885MEN1 2036/4885KMT2A 4441/4885 |
| US-10364232-B2 | Antibacterial compounds | FDPS, SQOR, NDUFS3 | GPR119 4679/4885MEN1 2036/4885KMT2A 4441/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | GPR119 1545/4885MEN1 4388/4885KMT2A 572/4885 |
| US-20180186768-A1 | Antibacterial Compounds | FDPS, SQOR, NDUFS3 | GPR119 4679/4885MEN1 2036/4885KMT2A 4441/4885 |
| US-20230014173-A1 | Antibacterial Compounds | FDPS, SQOR, NDUFS3 | GPR119 4679/4885MEN1 2036/4885KMT2A 4441/4885 |
| US-20200239434-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, SQOR, NDUFS3 | GPR119 4679/4885MEN1 2036/4885KMT2A 4441/4885 |
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | GPR119 887/4885MEN1 3393/4885KMT2A 492/4885 |
| US-20040063759-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | GPR119 416/4885MEN1 4730/4885KMT2A 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.